Precigen, Inc.

PGEN · NASDAQ

Precigen, Inc.PGEN · NASDAQ

Regular Market · Oct 30, 08:00 PM

$6.93+$0.29 +4.40%

After Hours $7.09 +$0.16 +2.26%

Oct 30, 08:25 PM

High: —
Low: —
Volume: —

Loading chart…

Ask Alva about PGEN

Precigen, Inc.

PGEN · Biotechnology

6.93 USD

+0.29 (+4.40%)

At Close

7.09 USD

+0.16 (+2.26%)

After hours

High
Low
Volume
Open
Prev Close
Turnover
Trailing P/E
Market Cap
Turnover Ratio
Free Float
Post-Market
VWAP
Range (%)
Volume Ratio
52-Wk High
52-Wk Low
Forward P/E
Beta

Precigen, Inc.

PGEN · NASDAQ

At Close

6.93 USD

+0.29 (+4.40%)

After hours 7.09 USD +0.16 (+2.26%)

High
Low
Volume
Open
Prev Close
Turnover
Trailing P/E
Market Cap
Turnover Ratio
Free Float
Post-Market
VWAP
Range (%)
Volume Ratio
52-Wk High
52-Wk Low
Forward P/E
Beta

Unusual Price Movement

PGEN rose sharply against a broad risk-off tape without a dated company catalyst.

PGEN gained about 5.6% while the S&P 500 and Nasdaq sold off and most specialty-biotech peers fell. The move stood apart from the peer group, with no company news behind it; Kymera's earnings and analyst actions were confined to KYMR.

Unusual Price Movement

PGEN rose sharply against a broad risk-off tape without a dated company catalyst.

Sources:

Kymera Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

Kymera Therapeutics Price Target Raised to $150.00/Share From $136.00 by Truist Securities

Ask Alva anything. @ for context, / for skills

Ask Alva about PGEN

PGEN rose sharply against a broad risk-off tape without a dated company catalyst. ⓘ

PGEN rose sharply against a broad risk-off tape without a dated company catalyst. ⓘ

PGEN rose sharply against a broad risk-off tape without a dated company catalyst.

PGEN rose sharply against a broad risk-off tape without a dated company catalyst.